Investigation of vancomycin use at 108 Military Central Hospital

  • Mạc Thị Mai Trường Đại học Dược Hà Nội
  • Nguyễn Trung Hà Bệnh viện Trung ương Quân đội 108
  • Đinh Đình Chính Bệnh viện Trung ương Quân đội 108
  • Lê Thị Phương Thảo Bệnh viện Trung ương Quân đội 108
  • Nguyễn Thị Thu Thủy Trường Đại học Dược Hà Nội
  • Nguyễn Thị Liên Hương Trường Đại học Dược Hà Nội

Main Article Content

Keywords

Vancomycin, nephrotoxicity, loading dose, maintenance dose, MRSA

Abstract

Objective: To describe ovancomycin use at 108 Military Central Hospital. Subject and method: A retrospective study was conducted on 61 medical records with vancomycin use at 108 Military Central Hospital from January 2020 to June 2020. Result: Mean age of patients was 59.9 years, the proportion of male patients was 75.4%. Discharge outcome: 68.9% with complete or partial recovery; 29.5% with death or worse outcome. Vancomycin was mainly prescribed empirically (90% with empirical indications and 10% with definitive indications). Microbiology tests were indicated in 96.7% of patients, of which 72.1% patients had positive results. Staphylococcus aureus was the most common gram (+) pathogen, of which 59.1% was MRSA. Loading dose was not used in 90% of patients. The most common maintenance dosing regimen was 1g every 12 hours (59.7%). However, this regimen was used on patients with very wide range of renal function (Clcr varied from 15.8ml/min to 155.3ml/min). Nephrotoxicity was occurred in 15 of 61 patients (24.6%), 13 patients of whom used concomitant medications with nephrotoxicity. Conclusion: The majority of patients weren’t received the loading dose (90%). The common maintenance dosing regimen was 1g every 12 hours, which was indicated in patients with various renal function (Clcr varied from 15.8ml/min to 155.3ml/min). The result of the study was very important basis for the implementation of a protocol for therapeutic monitoring of vancomycin.

Article Details

References

1. Lê Vân Anh (2015) Thử nghiệm can thiệp của dược sĩ lâm sàng vào việc sử dụng vancomycin nhằm đảm bảo hiệu quả và an toàn trong điều trị tại Bệnh viện Bạch Mai. Luận án Tiến sĩ.
2. Bệnh viện Bạch Mai (2019) Quy trình giám sát nồng độ thuốc trong máu và hiệu chỉnh liều vancomycin ở bệnh nhân người lớn của Bệnh viện Bạch Mai.
3. Álvarez Rocío, López Cortés Luis E et al (2016) Optimizing the clinical use of vancomycin. Antimicrobial agents and chemotherapy 60(5): 2601-2609.
4. American Society of Health-System Pharmacists (2009) Therapeutic monitoring of vancomycin in adults patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 66: 82-98.
5. Baptista JP, Sousa E et al (2012) Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents, 39(5): 420-423.
6. Drew HR, Sakoulas G (2018) Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults. Dostopno na: https://www. uptodate. com/contents/vancomycin-parenteral-dosingmonitoring-and-adverse-effects-in-adults.
7. Martin JH, Norris R et al (2010) Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev 31(1): 21-24.
8. NB Provincial Health Authorities Anti-Infective Stewardship Committee (2018) Vancomycin dosing and monitoring guidelines.
9. Rybak MJ, Le J et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77(11): 835-864.
10. Schulz TL, Pietruszka HM et al (2018) Intravenous vancomycin use - adult - inpatient/ambulatory clinical practice guideline.